Marshall Wace, LLP Gilead Sciences, Inc. Call Options Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $9.67 Million - $11 Million	127,200 New	127,200 $9.8 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $336,528 - $483,138	5,400 Added 8.59%	68,300 $5.86 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $3.75 Million - $4.28 Million	62,900 New	62,900 $3.88 Million
Q4 2021 Feb 14, 2022	SELL	$64.88 - $73.64 $6.09 Million - $6.91 Million	-93,900 Reduced 31.42%	205,000 $14.9 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $19.2 Million - $20.7 Million	283,300 Added 1816.03%	298,900 $20.9 Million
Q2 2021 Aug 13, 2021	SELL	$63.47 - $69.35 $1.56 Million - $1.7 Million	-24,500 Reduced 61.1%	15,600 $1.07 Million
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $2.41 Million - $2.75 Million	40,100 New	40,100 $2.59 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $114B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.